Pasithea Therapeutics (KTTA) Invested Capital (2021 - 2024)
Historic Invested Capital for Pasithea Therapeutics (KTTA) over the last 4 years, with Q3 2024 value amounting to $17.8 million.
- Pasithea Therapeutics' Invested Capital fell 3721.82% to $17.8 million in Q3 2024 from the same period last year, while for Sep 2024 it was $17.8 million, marking a year-over-year decrease of 3721.82%. This contributed to the annual value of $23.4 million for FY2023, which is 4495.37% down from last year.
- According to the latest figures from Q3 2024, Pasithea Therapeutics' Invested Capital is $17.8 million, which was down 3721.82% from $16.2 million recorded in Q2 2024.
- Over the past 5 years, Pasithea Therapeutics' Invested Capital peaked at $51.5 million during Q2 2022, and registered a low of $16.2 million during Q2 2024.
- In the last 4 years, Pasithea Therapeutics' Invested Capital had a median value of $35.6 million in 2023 and averaged $33.8 million.
- Its Invested Capital has fluctuated over the past 5 years, first skyrocketed by 18399.68% in 2022, then tumbled by 5455.71% in 2024.
- Pasithea Therapeutics' Invested Capital (Quarter) stood at $51.4 million in 2021, then decreased by 17.33% to $42.5 million in 2022, then tumbled by 44.95% to $23.4 million in 2023, then fell by 23.87% to $17.8 million in 2024.
- Its last three reported values are $17.8 million in Q3 2024, $16.2 million for Q2 2024, and $19.9 million during Q1 2024.